The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Market share and costs of biologic therapies for inflammatory bowel disease in the USA
Open accessAbstract
Summary: Background: Real‐world data quantifying the costs of increasing use of biologics in inflammatory bowel disease (IBD) are unknown. Aim: To determine the outpatient IBD drug utilization trends, relative market share, and costs in the USA during a 9‐year period. Methods: The Truven MarketScan® Database was analysed for patients with Crohn's disease (CD) and ulcerative colitis (UC) during 2007‐2015. National drug codes were used to identify prescription drugs; Healthcare Common Procedure Coding System J‐codes were used to capture biologic out‐patient infusions. Proportion of drug usage, relative market share and per‐member per‐year (PMPY) costs were analysed for biologics, immunomodulators, 5‐ASA s and corticosteroids. Results: In 415 405 patients (188 842 CD; 195 183 UC; 31 380 indeterminate colitis; 54.67% female), utilization trends show a consistent rise in the market share of biologics during the 9‐year study period. The proportion of patients using biologics increased from 21.8% to 43.8% for CD and 5.1%‐16.2% for UC. This contrasts a small decrease in immunomodulator and 5‐ASA use for CD and relative constancy of other classes including corticosteroids‐only use as primary IBD medication from 2007 to 2015. The average biologic‐taking patient accounted for $25 275 PMPY in 2007 and $36 051 PMPY in 2015. The average paediatric biologic‐taking patient accounted for $23 616 PMPY in 2007 and $41 109 PMPY in 2015. In all patients, the share of costs for biologics increased from 72.9% in 2007 to 85.7% in 2015 (81.7% in 2007 to 94.9% in 2015 in paediatrics). Conclusion: The vast majority of costs allocated to out‐patient IBD medications in the USA is attributed to increasing use of biologic therapies despite the relative minority of biologic‐taking patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform
Kesselheim, A. S., Avorn, J., & Sarpatwari, A. (2016) · JAMA · doi:10.1001/jama.2016.11237 · Cited by 592
Cited by
JAK–STAT pathway targeting for the treatment of inflammatory bowel disease
Salas, A., Hernandez-Rocha, C., Duijvestein, M., Faubion, W., McGovern, D., Vermeire, S., Vetrano, S., & Vande Casteele, N. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-0273-0 · Cited by 635
The Cost of Inflammatory Bowel Disease: An Initiative From the Crohn’s & Colitis Foundation
Park, K. T., Ehrlich, O. G., Allen, J. I., Meadows, P., Szigethy, E. M., Henrichsen, K., Kim, S. C., Lawton, R. C., Murphy, S. M., Regueiro, M., et al. (2020) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izz104 · Cited by 431
Self-citationBreaking through the therapeutic ceiling: what will it take?
Raine, T., & Danese, S. (2022) · Gastroenterology · doi:10.1053/j.gastro.2021.09.078 · Cited by 160
Truyens, M., Lobatón, T., Ferrante, M., Bossuyt, P., Vermeire, S., Pouillon, L., Dewint, P., Cremer, A., Peeters, H., Lambrecht, G., et al. (2022) · Gastroenterology · doi:10.1053/j.gastro.2022.07.052 · Cited by 48
Metadata
- Authors
- Yu, H., MacIsaac, D., Wong, J. J., Sellers, Z. M., Wren, A. A., Bensen, R., Kin, C., & Park, K. T.
- Venue
- Alimentary Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2017-11-22
- Volume
- 47
- Issue
- 3
- Pages
- 364-370
- ISSN
- 0269-2813 (ISSN-L)
- 1365-2036
- OpenAlex
- W2770190609
- Cited by
- 180
- References
- 1
- FWCI
- 11.29
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.